Drug intelligence / Profile preview

RS-86

Development stage: Discontinued
Lead developer: Novartis
Modality: Small Molecules

Overview

RS-86 is a synthetic small molecule drug that acts as an agonist at muscarinic acetylcholine receptors (mAChRs). It is classified as a parasympathomimetic agent and directly stimulates muscarinic receptors in the nervous system. The compound was originally developed for potential use in neurological disorders such as Alzheimer's disease but development was discontinued. Its mechanism of action involves mimicking the effects of acetylcholine by activating mAChRs[1][3].

Other names: 2,8-diazaspiro(4.5)decane-1,3-dione 2-ethyl-8-methyl-2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione hydrobromide

Targets

M1 (Muscarinic acetylcholine receptor M1)

Beyond the preview

Go deeper on RS-86.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RS-86.

Explore the full profile